Advancements in Cell and Gene Therapy Manufacturing

This chapter covers the approval of AMTAGVY via the Accelerated Approval Pathway, along with plans for future trials and the expansion of manufacturing facilities by Iovans. It also discusses MIP Discovery's Series A financing round to enhance downstream processing of cell and gene therapies, highlighting the potential of their non-biological affinity reagents to improve efficiency and affordability in therapy development.